After Ncardia launched its affiliate company Cellistic last week, dedicated to making large-scale allogeneic cell therapy production a reality, they are proud to now enter a strategic collaboration with Quell Therapeutics, to develop an iPSC-derived allogeneic T-regulatory cell therapy platform.
MedtechPartners is a strong network of experts in the medical technology industry. At this meeting, promising start-ups pitched their innovation and were matched to the partners and audience. The MedtechMeeting ended with networking drinks. All in all it was a great succes!
The Hague - 22 April 2022. At the Proefdiervrij Event Anya Biotech was announced the winner of the 2nd edition of the Proefdiervrij Venture Challenge. Harsha Devalla, Marc Roelofs and Sander van Leeuwe of Anya Biotech develop animal-free re
Eindhoven, The Netherlands, 25 April 2022 – Venture Challenge alumnus STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million see
Ncardia launches CellisticTM, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.
Een investering van € 5 miljard en daarnaast een reservering van € 1,3 miljard voor in totaal 28 projecten moeten zorgen voor duurzame economische groei in Nederland.